Related Experiment Video
Updated: Jul 15, 2026
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer
M Chien1, M Astumian, D Liebowitz
1Section of Urology, University of Chicago, IL 60637, USA.
Purpose:
To determine the in vitro effects of flavopiridol on bladder cancer cell lines, immortalized urothelial cell lines, and normal urothelial cells well characterized for defects in p53, pRb, and p16.
Methods:
Growth inhibition was assessed via an MTT assay and apoptosis via DAPI nuclear staining. Cell cycle analysis was performed via propidium iodide staining and fluorescent activated cell sorting (FACS). Multidrug-resistant cells were generated by continuous exposure to doxorubicin.
Results:
Growth inhibition was not correlated with inactivation of p53, pRb, or p16. All cells experienced G2/M arrest within 24 h of flavopiridol exposure. Modest apoptosis was observed but required 72 h of continuous drug exposure to become evident. There was no obvious synergistic or antagonistic toxicity when flavopiridol was combined with radiotherapy or cisplatin dosed at the IC50 despite the observation that radiotherapy and flavopiridol led to more profound G2/M arrest than either agent alone. Doxorubicin-resistant cells, demonstrated to overexpress the MDR1 multi-drug-resistance protein were equally as sensitive to flavopiridol as the parental cells.
Conclusions:
Flavopiridol is a novel cell cycle inhibitor that may be a useful agent in bladder cancers with tumor suppressor gene alterations and/or multidrug resistance.
Insights
Flavopiridol effectively inhibits bladder cancer cell growth by causing G2/M cell cycle arrest. This novel agent shows promise for treating bladder cancers, including those with multidrug resistance or tumor suppressor gene alterations.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Bladder cancer treatment faces challenges with tumor suppressor gene alterations and multidrug resistance.
- Understanding novel therapeutic agents like flavopiridol is crucial for advancing bladder cancer care.
Purpose of the Study:
- To investigate the in vitro effects of flavopiridol on various human bladder cell lines.
- To assess flavopiridol's impact on cell growth, apoptosis, and cell cycle progression.
- To evaluate flavopiridol's efficacy in multidrug-resistant and genetically altered urothelial cells.
Main Methods:
- MTT assays for growth inhibition and DAPI staining for apoptosis.
- Propidium iodide staining and Fluorescence-Activated Cell Sorting (FACS) for cell cycle analysis.
- Generation of doxorubicin-resistant cell lines to model multidrug resistance.
Main Results:
- Flavopiridol induced G2/M cell cycle arrest in all tested cell lines within 24 hours.
- Apoptosis was observed after 72 hours of continuous flavopiridol exposure.
- Flavopiridol demonstrated efficacy against multidrug-resistant cells and showed no significant synergistic or antagonistic effects with cisplatin or radiotherapy.
Conclusions:
- Flavopiridol is a potent cell cycle inhibitor with potential therapeutic value in bladder cancer.
- Its activity is independent of p53, pRb, or p16 status, suggesting broad applicability.
- Flavopiridol may be a valuable option for bladder cancers exhibiting multidrug resistance or specific tumor suppressor gene alterations.
